What can we learn from phase II adjuvant trials in melanoma?

Por Keilholz, U, Suciu, S, Eggermont, A M M
Publicado em 2000

Rheumatic disease following immunotherapy.

Por Scheibenbogen, C, Keilholz, U, Pezzutto, A, Hunstein, W
Publicado em 1993

Peptide vaccination induces specific effector and memory T cells but fails to enhance preexisting T cell immunity

Por Thiel E, Asemissen AM, Nagorsen D, Keilholz U, Letsch A, Scheibenbogen C
Publicado em 2004-07-01

Correlation of positive RT-PCR for tyrosinase in peripheral blood of malignant melanoma patients with clinical stage, survival and other risk factors

Por Proebstle, T M, Jiang, W, Högel, J, Keilholz, U, Weber, L, Voit, C
Publicado em 2000

Increased expression of integrins on fibroblast-like synoviocytes from rheumatoid arthritis in vitro correlates with enhanced binding to extracellular matrix proteins

Por Rinaldi, N, Schwarz-Eywill, M, Weis, D, Leppelmann-Jansen, P, Lukoschek, M, Keilholz, U, Barth, T
Publicado em 1997

Differential expression and functional behaviour of the αv and β3 integrin subunits in cytokine stimulated fibroblast-like cells derived from synovial tissue of rheumatoid arthriti...

Por Rinaldi, N., Weis, D, Brado, B, Schwarz-Eywill, M, Lukoschek, M, Pezzutto, A, Keilholz, U, Barth, T
Publicado em 1997

Phase I/II trial of cilengitide with cetuximab, cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell cancer of the head and neck: findings of the phase I part

Por Vermorken, J B, Guigay, J, Mesia, R, Trigo, J M, Keilholz, U, Kerber, A, Bethe, U, Picard, M, Brummendorf, T H
Publicado em 2011

Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial

Por Leyvraz, S., Piperno-Neumann, S., Suciu, S., Baurain, J. F., Zdzienicki, M., Testori, A., Marshall, E., Scheulen, M., Jouary, T., Negrier, S., Vermorken, J. B., Kaempgen, E., Durando, X., Schadendorf, D., Gurunath, R. Karra, Keilholz, U.
Publicado no Ann Oncol (2014)

Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/I...

Por Vermorken, J. B., Peyrade, F., Krauss, J., Mesía, R., Remenar, E., Gauler, T. C., Keilholz, U., Delord, J. P., Schafhausen, P., Erfán, J., Brümmendorf, T. H., Iglesias, L., Bethe, U., Hicking, C., Clement, P. M.
Publicado em 2014

Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial(...

Por Clement, P. M., Gauler, T., Machiels, J. P., Haddad, R. I., Fayette, J., Licitra, L. F., Tahara, M., Cohen, E. E. W., Cupissol, D., Grau, J. J., Guigay, J., Caponigro, F., de Castro, G., de Souza Viana, L., Keilholz, U., del Campo, J. M., Cong, X. J., Ehrnrooth, E., Vermorken, J. B.
Publicado no Ann Oncol (2016)

Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial

Por Gisslinger, Heinz, Gotic, Mirjana, Holowiecki, Jerzy, Penka, Miroslav, Thiele, Juergen, Kvasnicka, Hans-Michael, Kralovics, Robert, Petrides, Petro E., Gastl, G., Gisslinger, B., Muellauer, L., Schlögl, E., Indrak, K., Pytlik, R., Briere, J., Kiladjian, J.J., Beykirch, M., Gaede, B., Griesshammer, M., Herbrik-Zipp, M., Hurtz, H.J., Jacobs, G., Jäcki, S.H., Keilholz, U., Mezger, J., Schlag, P., Schriever, F., Masszi, T., Sacchi, S., Griniptì, R., Tavoriene, I., Dmoszynska, A., Hellman, A., Jedrzejczak, W.W., Robak, T., Skotnicki, A., Goh, Y.T., Cernelc, P.
Publicado em 2013